Compare Novartis AG (NVS) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Unilever plc — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Unilever plc trades at $62.2 (market cap $132.07B). The key difference: Novartis AG is far larger — about 2.1× Unilever plc's market cap, and Unilever plc pays the higher dividend (3.48%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Unilever plc for 112 Days on average.
| NVS | UL | |
|---|---|---|
Market Cap | $274.00B | $132.07B |
Volume | 1,852,137 | 2,873,862 |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $74.59 |
52-Week Low | $121.80 | $55.05 |
Typical Hold Time | 82 Days | 112 Days |
Enterprise Value | $315.32B | $157.21B |
Dividend Yield | 3.31% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Unilever (UL) trades at $61.94, up 1.88% today, amid bearish technical signals and mixed earnings performance. The stock shows strong profitability with 18.32% net margins and 54.56% ROE, though recent quarters saw EPS misses. Cash flow turned negative in 2025 at -$2.08B due to increased investing activity. The company is restructuring its portfolio, including the planned $65B food business merger with McCormick, while facing regulatory scrutiny in the UK.
Outlook remains cautious with analyst consensus divided (24% Buy, 51% Hold) and technical indicators bearish. Investment appeal lies in emerging market exposure and dividend stability, but risks include integration challenges from the McCormick deal, competitive pressures, and inconsistent earnings delivery. Valuation at 21.32 P/E appears reasonable given margins but requires execution improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
